RCUS vs. ANIP, AKRO, MORF, GYRE, KNSA, PTGX, XNCR, DVAX, ARDX, and DAWN
Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), Morphic (MORF), Gyre Therapeutics (GYRE), Kiniksa Pharmaceuticals (KNSA), Protagonist Therapeutics (PTGX), Xencor (XNCR), Dynavax Technologies (DVAX), Ardelyx (ARDX), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical preparations" industry.
Arcus Biosciences (NYSE:RCUS) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends.
ANI Pharmaceuticals received 244 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 64.59% of users gave ANI Pharmaceuticals an outperform vote while only 64.41% of users gave Arcus Biosciences an outperform vote.
In the previous week, ANI Pharmaceuticals had 7 more articles in the media than Arcus Biosciences. MarketBeat recorded 10 mentions for ANI Pharmaceuticals and 3 mentions for Arcus Biosciences. ANI Pharmaceuticals' average media sentiment score of 0.96 beat Arcus Biosciences' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.
Arcus Biosciences has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
Arcus Biosciences presently has a consensus price target of $41.25, suggesting a potential upside of 162.74%. ANI Pharmaceuticals has a consensus price target of $80.00, suggesting a potential upside of 18.96%. Given Arcus Biosciences' higher probable upside, equities research analysts plainly believe Arcus Biosciences is more favorable than ANI Pharmaceuticals.
ANI Pharmaceuticals has a net margin of 3.86% compared to Arcus Biosciences' net margin of -262.39%. ANI Pharmaceuticals' return on equity of 18.06% beat Arcus Biosciences' return on equity.
92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 12.3% of Arcus Biosciences shares are owned by insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ANI Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ANI Pharmaceuticals beats Arcus Biosciences on 13 of the 18 factors compared between the two stocks.
Get Arcus Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcus Biosciences Competitors List
Related Companies and Tools
